Immunotherapy for LELC: Case Report and a Focused Review - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Clinical Lung Cancer Year : 2019

Immunotherapy for LELC: Case Report and a Focused Review


Lymphoepithelioma-like carcinoma of the lung (LELC) is a rare, Epstein-Barr virus-associated tumor. LELC occurs mostly in young, Asian nonsmokers. A few hundred cases have been reported, mostly from retrospective Asian studies. Optimal treatment has not been clearly established. Treatment options are based on surgery for early stage and on cisplatin-based chemotherapy as first-line therapy for metastatic disease. Prognosis may seem better than for other types of nonesmall-cell lung cancer, but it remains poor in advanced disease, with a median survival of 24 months, and new treatments options are still warranted. Immunotherapies are now key players in the treatment of non esmall-cell lung cancer. However, few data are available for this rare histologic subgroup. We have reviewed the available data on LELC with a focus on the first few cases reported with a response to a programmed cell death 1 inhibitor.
Embargoed file
Embargoed file
Ne sera jamais visible

Dates and versions

inserm-03891665 , version 1 (09-12-2022)



Marie Darrason, Antoine Martin, Michael Soussan, Kader Chouahnia, Marie-Christine Pailler, et al.. Immunotherapy for LELC: Case Report and a Focused Review. Clinical Lung Cancer, 2019, 20 (3), pp.e393 - e401. ⟨10.1016/j.cllc.2018.12.008⟩. ⟨inserm-03891665⟩
8 View
5 Download



Gmail Facebook Twitter LinkedIn More